Astrana Health director sells 8.5K shares

After Astrana Health repurchased 8,500 shares at $37.09 on Aug. 31, Kitayama now holds 24,337 shares, including restricted shares vesting by June 10, 2027.

Rhea-AI Filing Summary

Astrana Health, Inc. (ASTH) reported that director Mitchell W. Kitayama disposed of shares of common stock in a transaction recorded as a disposition to the issuer. On 2026-08-31, 8,500 shares were repurchased by Astrana Health at $37.09 per share. Following this repurchase, Kitayama directly holds 24,337 shares, including 4,991 shares of restricted stock that will vest on the earlier of June 10, 2027 or the company’s 2027 annual meeting of stockholders.

Insider Trade Summary

Disposition: 8,500 shares

Disposition 1 txn

Insider Kitayama Mitchell W

Role Director

Type	Security	Shares	Price	Value
Disposition	Common Stock F1, F2	8,500	$37.09	$315K

Holdings After Transaction: Common Stock — 24,337 shares (Direct)

Footnotes (2)

1. F1. These shares were repurchased by the Issuer.
2. F2. Includes 4,991 shares of restricted stock, which will vest on the earlier of June 10, 2027 or the date of the Issuer's 2027 annual meeting of stockholders.

Key Figures

Shares disposed: 8,500 shares of Common Stock Transaction price per share: $37.09 per share Shares held after transaction: 24,337 shares +2 more

5 metrics

Shares disposed 8,500 shares of Common Stock Disposition to issuer on 2026-08-31

Transaction price per share $37.09 per share Issuer repurchase of 8,500 shares on 2026-08-31

Shares held after transaction 24,337 shares Direct ownership of Mitchell W. Kitayama following disposition

Restricted stock included in holdings 4,991 shares of restricted stock Part of post-transaction direct holdings

Restricted stock vesting date Earlier of June 10, 2027 or 2027 annual meeting date Vesting schedule for 4,991 restricted shares

Key Terms

Disposition to issuer, restricted stock, annual meeting of stockholders

3 terms

Disposition to issuer financial

"transaction coded as a disposition to the issuer"

restricted stock financial

"Includes 4,991 shares of restricted stock, which will vest"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

annual meeting of stockholders financial

"or the date of the Issuer's 2027 annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Astrana Health (ASTH) disclose in this Form 4?

The filing reports that director Mitchell W. Kitayama disposed of 8,500 shares of Astrana Health common stock on 2026-08-31 in a transaction coded as a disposition to the issuer, with the shares repurchased by Astrana Health.

At what price were the Astrana Health (ASTH) shares repurchased from the director?

Astrana Health repurchased the 8,500 shares of common stock from director Mitchell W. Kitayama at a price of $37.09 per share, as reported in the Form 4 transaction details.

How many Astrana Health (ASTH) shares does Mitchell W. Kitayama hold after this transaction?

After the 8,500-share disposition to the issuer, Mitchell W. Kitayama directly holds 24,337 shares of Astrana Health common stock, according to the post-transaction holdings reported in the Form 4.

How many restricted Astrana Health (ASTH) shares does the director hold and when do they vest?

The director’s post-transaction holdings include 4,991 shares of restricted stock, which will vest on the earlier of June 10, 2027 or the date of Astrana Health’s 2027 annual meeting of stockholders.

Was this Astrana Health (ASTH) insider trade made under a Rule 10b5-1 trading plan?

No. The Form 4 indicates the Rule 10b5-1 checkbox is not affirmed (aff_10b5_one is false), and the footnotes do not state that this transaction was made pursuant to a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/01/2026 - 08:44 PM EDT Accepted by SEC EDGAR 09/01/2026 - 08:43 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kitayama Mitchell W

(Last) (First) (Middle)

C/O ASTRANA HEALTH, INC.

1668 S. GARFIELD AVE, 2ND FLOOR

(Street)

ALHAMBRA CALIFORNIA 91801

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Astrana Health, Inc. [ ASTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/31/2026		D(1)		8,500	D	$37.09	24,337(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were repurchased by the Issuer.

2. Includes 4,991 shares of restricted stock, which will vest on the earlier of June 10, 2027 or the date of the Issuer's 2027 annual meeting of stockholders.

	/s/ Kathy Diep, as Attorney-in-Fact	09/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)